Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder
- 15 December 2023
- journal article
- research article
- Published by Springer Nature in Journal of Autism and Developmental Disorders
- Vol. 55 (9) , 3387-3394
Abstract
Neuroinflammatory mechanisms have been implicated in the pathophysiology of autism spectrum disorder (ASD). Minocycline is a matrix metalloproteinase inhibitor 9 (MMP9) inhibitor tetracycline antibiotic with known anti-inflammatory properties. In preclinical animal models of ASD, minocycline has demonstrated potential positive effects on phenotypes that may have relevance to ASD. We conducted the first placebo-controlled study of minocycline in ASD. This double-blind, placebo-controlled crossover trial employed four week treatment periods with a two week washout period. Twenty-four 12–22 year olds (mean age 17.4 years; range 12.9–22.5 years) with ASD were enrolled. Overall minocycline was well tolerated. No minocycline-associated clinical changes were noted with treatment on any performance or clinician or caregiver completed measures were noted. We hypothesize that either minocycline does not have potential therapeutic effects in ASD or our project was underpowered to define potential subject subgroups who may potentially respond positively to this drug.Keywords
Funding Information
- Autism Speaks
This publication has 49 references indexed in Scilit:
- Electrocortical changes associated with minocycline treatment in fragile X syndromeJournal of Psychopharmacology, 2013
- Long-lasting effects of minocycline on behavior in young but not adult Fragile X miceNeuroscience, 2013
- A pilot open-label trial of minocycline in patients with autism and regressive featuresJournal of Neurodevelopmental Disorders, 2013
- Matrix Metalloproteinases and Minocycline: Therapeutic Avenues for Fragile X SyndromeNeural Plasticity, 2012
- Evidence of microglial activation in autism and its possible role in brain underconnectivityNeuron Glia Biology, 2011
- Open-label add-on treatment trial of minocycline in fragile X syndromeBMC Neurology, 2010
- Microglial Activation and Increased Microglial Density Observed in the Dorsolateral Prefrontal Cortex in AutismBiological Psychiatry, 2010
- Minocycline: A neuroprotective agent for hypoxic‐ischemic brain injury in the neonate?Journal of Neuroscience Research, 2008
- Cerebrospinal Fluid and Serum Markers of Inflammation in AutismPediatric Neurology, 2005
- Neuroglial activation and neuroinflammation in the brain of patients with autismAnnals of Neurology, 2004